Shopping Cart 0
Cart Subtotal
USD 0

Optic Neuritis-Pipeline Review, H1 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Optic Neuritis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuritis-Pipeline Review, H1 2017, provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape.

Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff's phenomenon and flashing lights. Risk factors include age and genetic mutations.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Optic Neuritis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 7 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Optic Neuritis-Overview

Optic Neuritis-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Optic Neuritis-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Optic Neuritis-Companies Involved in Therapeutics Development

2-BBB Medicines BV

Biogen Inc

Bionure Farma SL

Commence Bio Inc

Lipocure Ltd

Meta-IQ ApS

Neuralstem Inc

Teijin Pharma Ltd

Optic Neuritis-Drug Profiles

2B-3201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BN-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etomoxir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gypenoside-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylprednisolone sodium phosphate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NSI-566-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

opicinumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Optic Neuritis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Optic Neuritis-Dormant Projects

Optic Neuritis-Discontinued Products

Optic Neuritis-Product Development Milestones

Featured News & Press Releases

Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis

Oct 01, 2015: Biogen Presents Phase 2 Data On Anti-LINGO-1 at ECTRIMS Congress

Apr 14, 2015: Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

Jan 08, 2015: Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial In People With Acute Optic Neuritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Optic Neuritis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017


List Of Table

List of Tables

Number of Products under Development for Optic Neuritis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Optic Neuritis-Pipeline by 2-BBB Medicines BV, H1 2017

Optic Neuritis-Pipeline by Biogen Inc, H1 2017

Optic Neuritis-Pipeline by Bionure Farma SL, H1 2017

Optic Neuritis-Pipeline by Commence Bio Inc, H1 2017

Optic Neuritis-Pipeline by Lipocure Ltd, H1 2017

Optic Neuritis-Pipeline by Meta-IQ ApS, H1 2017

Optic Neuritis-Pipeline by Neuralstem Inc, H1 2017

Optic Neuritis-Pipeline by Teijin Pharma Ltd, H1 2017

Optic Neuritis-Dormant Projects, H1 2017

Optic Neuritis-Discontinued Products, H1 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Optic Neuritis Therapeutic Products under Development, Key Players in Optic Neuritis Therapeutics, Optic Neuritis Pipeline Overview, Optic Neuritis Pipeline, Optic Neuritis Pipeline Assessment


Companies

2-BBB Medicines BV, Biogen Inc, Bionure Farma SL, Commence Bio Inc, Lipocure Ltd, Meta-IQ ApS, Neuralstem Inc, Teijin Pharma Ltd